Skip to main content
. 2023 Jan 12;102(3):651–661. doi: 10.1007/s00277-023-05084-x

Fig. 2.

Fig. 2

Kaplan–Meier curves of overall survival (a), progression-free survival (b), cumulative incidence of non-relapse mortality (c), and relapse (d) after propensity score matching. Flu/Bu2, fludarabine with reduced-intensity busulfan; Flu/Bu4, fludarabine with myeloablative busulfan